Table 1. Demographic, clinical and biochemical characteristics of the 21 patients included in the longitudinal analysis and the cross-sectional study (n = 150).
| Variable | n = 21 | n = 150 |
|---|---|---|
| Age (years) § | 70.0 (62.0–76.5) | 71.0 (58.7–81.0) |
| BMI a, ¶ | 26.3 (23.1–30.2) | 26.1 (22.1–30.2) |
|
Gender (n, %) Male Female |
12 (57.1) 9 (42.9) |
85 (56.7) 65 (43.3) |
| Renal disease | ||
| Unknown (%) | 38.1 | 36.0 |
| Diabetes (%) | 14.3 | 18.0 |
| Hypertension (%) | 4.8 | 5.3 |
| Glomerulonephritis (%) | 14.3 | 10.7 |
| Polycystic (%) | 9.5 | 14.0 |
| Others (%) | 19.0 | 16.0 |
| Comorbidities | ||
| Hypertension (%) | 71.4 | 83.3 |
| Diabetes (%) | 23.8 | 29.3 |
| Coronary artery disease (%) | 23.8 | 21.3 |
| Cerebrovascular disease (%) | 14.3 | 12.7 |
| Charlson Comorbidity index § | 4.0 (3.0–5.0) | 4.0 (2.0–5.0) |
| Vascular Access | ||
| AV Fistula, n (%) | 11 (52.4) | 102 (68.0) |
| Catheters, n (%) | 6 (28.6) | 41 (27.3) |
| Grafts, n (%) | 4 (19) | 7 (4.7) |
| Dialysate Calcium 3 mEq/L (n, %) | 21 (100) | 131 (87.3) |
|
Dialysis technique HF-HD (n, %) OL-HDF (n, %) |
21 (100) 0 |
69 (46) 81 (54) |
| Dialysis vintage (months) b, § | 53.7 (33.7–83.8) | 50.1 (17.5–82.1) |
| Dialysis Duration (min) § | 245.0 (243.0–250.0) | 250.0 (240.0–250.0) |
| KtV § | 2.0 (1.8–2.4) | 1.9 (1.7–2.3) |
| Kt (L/session) § | 60.1 (48.8–66.65) | 59.8 (52.0–64.0) |
| Albumin (g/L) | 3.6 (3.3–3.8) | 3.7 (3.4–3.9) |
| Hb (g/L) c, § | 11.2 (10.4–11.9) | 11.2 (10.4–12.0) |
| TSAT (%)d, § | 29.0 (21.5–37.5) | 26.0 (21.0–34.0) |
| Ferritin (ng/dl) § | 529.0 (351.5–757.0) | 468.5 (327.0–742.2) |
| hs-CRP (mg/L) e, § | 8.0 (4.1–11.4) | 7.2 (3.5–10.8) |
| Ca (mg/dL) e, § | 8.9 (8.5–9.3) | 8.8 (8.4–9.2) |
| iCa (mEq/L) f, § | 2.2 (2.1–2.2) | 2.2 (2.1–2.3) |
| P (mg/dl) g, § | 4.3 (3.6–5.5) | 4.3 (3.7–5.3) |
| Alkaline phosphatase (U/L) § | 85.5 (74.0–108.7) | 90.5 (71.0–121.0) |
| iPTH (pg/ml) h, § | 284.0 (199.5–445.0) | 263.0 (151.7–434.5) |
| 25(OH)D (ng/ml) i, §, * | 9.2 (8.5–18.) | 8.1 (6.9–10.5) |
| 1,25 (OH)2 D (pg/ml) j, §, * | 9.2 (7.7–10.3) | 11.0 (5.0–14.8) |
| iFGF23 (pg/ml) k, § | 614.0 (346.0–958.5) | 502.5 (167.0–1224.5) |
| cFGF23 (RU/ml) l, § | 880.0 (547.5–1443.5) | 900.5 (400.2–1819.7) |
| Phosphate Binders (n, %) | 21 (100) | 67 (44.7) |
| Paricalcitol (n, %) | —— | 41 (27.3) |
| Cinacalcet (n, %) | —— | 20 (13.3) |
¶ Mean ± Standard deviation (SD)
§ Median and Interquartile Range (IQR)
a BMI, Body Mass Index
b Dialysis Vintage, Time since the initiation of dialysis
c Hb, Hemoglobin
d TSAT, Transferrin Saturation
e hs-CRP, C Reactive Protein
f iCa, Ionized Serum Calcium
g P, Serum Phosphate
h PTH, Intact Parathyroid Hormone
i 25 (OH)D, 25 hydroxy vitamin D (calcidiol)
j 1,25 (OH)2 D, 1,25 dihydroxy vitamin D (calcitriol)
k i-FGF23, Intact Fibroblast Growth Factor 23
l c-FGF23, C-Terminal Fibroblast Growth Factor 23.
- Normal range: serum P were between (2.4 to 4.5 mg/dL); serum iCa (1.13–1.32 mmol/L); 25 (OH) D (8–42 ng/mL); 1,25 (OH)2 D3 (18–71 pg/mL); iPTH (15–65 pg/mL); hs-CRP0 (3 to 5 mg/L); albumin (3.4 to 5 g/dL) and Alkaline Phosphatase (35 to 104 U/L).
- To convert iCa from mEq/L to mmol/L, multiply by 0.5.